We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+54.45%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$4.6B
AUM Growth
+$1.51B
Cap. Flow
+$217M
Cap. Flow %
4.71%
Top 10 Hldgs %
30.3%
Holding
146
New
24
Increased
37
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$75.3M
2
TT icon
Trane Technologies
TT
+$39.3M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$35.1M
4
EXAS
Exact Sciences
EXAS
+$27.8M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$22.1M

Top Sells

Rank Stock Value
1
XYL icon
Xylem
XYL
+$51.6M
2
TWLO icon
Twilio
TWLO
+$48M
3
ZGNX
Zogenix, Inc.
ZGNX
+$45M
4
VRNS icon
Varonis Systems
VRNS
+$26.7M
5
SAGE
Sage Therapeutics
SAGE
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 45.14%
2 Technology 22.43%
3 Industrials 8.89%
4 Consumer Discretionary 7.31%
5 Communication Services 3.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
51
DELISTED
Zogenix, Inc.
ZGNX
$32.7M 0.71%
1,211,300
-1,630,000
-57% -$45M
MGA icon
52
Magna International
MGA
$19B
$32.7M 0.71%
734,700
+16,700
+2% +$660K
PANW icon
53
Palo Alto Networks
PANW
$265B
$32.6M 0.71%
851,022
– –
RCKT icon
54
Rocket Pharmaceuticals
RCKT
$351M
$32.4M 0.71%
1,550,000
+135,000
+10% +$2.43M
NOVT icon
55
Novanta
NOVT
$4.95B
$29.9M 0.65%
280,000
– –
FVRR icon
56
Fiverr
FVRR
$330M
$29.4M 0.64%
+398,299
New +$20.5M
DDOG icon
57
Datadog
DDOG
$95.6B
$28.6M 0.62%
329,000
– –
STSA
58
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$28.3M 0.61%
983,382
– –
ROL icon
59
Rollins
ROL
$18.5B
$27.1M 0.59%
958,500
-201,000
-17% -$5.38M
TPTX
60
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$24.7M 0.54%
+383,000
New +$22.1M
VCYT icon
61
Veracyte
VCYT
$4.77B
$24.1M 0.52%
930,000
– –
HASI icon
62
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
$23.9M 0.52%
839,100
-5,500
-0.7% -$150K
CRNX icon
63
Crinetics Pharmaceuticals
CRNX
$8.85B
$23.6M 0.51%
1,347,000
+400,000
+42% +$6.82M
QURE icon
64
uniQure
QURE
$2.93B
$22.5M 0.49%
500,000
– –
OKTA icon
65
Okta
OKTA
$24.4B
$21.6M 0.47%
108,000
– –
CGNX icon
66
Cognex
CGNX
$10.4B
$21.4M 0.47%
+359,000
New +$19.5M
AY
67
DELISTED
Atlantica Sustainable Infrastructure plc Ordinary Shares
AY
$21.4M 0.47%
736,000
-125,700
-15% -$3.17M
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
$20.6M 0.45%
+2,547,000
New +$15.8M
KALV
69
DELISTED
KalVista Pharmaceuticals
KALV
$20.3M 0.44%
1,680,000
– –
MDB icon
70
MongoDB
MDB
$26.2B
$19.5M 0.42%
86,000
– –
REGN icon
71
Regeneron Pharmaceuticals
REGN
$77.4B
$19.3M 0.42%
30,900
– –
SWKS icon
72
Skyworks Solutions
SWKS
$9.4B
$18.9M 0.41%
148,200
+13,000
+10% +$1.44M
DNTH icon
73
Dianthus Therapeutics
DNTH
$6.16B
$17.7M 0.39%
147,478
+35,625
+32% +$5.02M
SGEN
74
DELISTED
Seagen Inc. Common Stock
SGEN
$17.4M 0.38%
102,500
– –
XPO icon
75
XPO
XPO
$23.4B
$17M 0.37%
636,107
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Eventide Asset Management held 146 positions worth $4.6B, up 49% from $3.09B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Eventide Asset Management deployed $217M of net new capital in Q2 2020, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Pliant Therapeutics: 2,838,125 shares worth $88.4M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 44% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Twilio, an estimated $48M trimmed.

  • Eventide Asset Management's largest Q2 2020 buy was Pliant Therapeutics: 2,838,125 shares worth $88.4M.
  • Eventide Asset Management added most to Trane Technologies in Q2 2020, an estimated $39.3M increase.
  • Eventide Asset Management's biggest Q2 2020 reduction was Twilio, cutting an estimated $48M.
  • Eventide Asset Management fully exited Xylem in Q2 2020, selling an estimated $51.6M.
  • Eventide Asset Management's ten largest holdings make up 30% of its $4.6B portfolio in Q2 2020.
  • Eventide Asset Management opened 24 new positions and closed 12 in Q2 2020.
  • Eventide Asset Management's portfolio value rose 49% quarter-over-quarter to $4.6B.

Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.